Table 2.
Prognostic performance for hepatocellular carcinoma in different staging systems.
| Staging | 2004–2007 | 2008–2011 | 2012–2015 | |||
|---|---|---|---|---|---|---|
| Homogeneity (Wald χ2) | AICc | Homogeneity (Wald χ2) | AICc | Homogeneity (Wald χ2) | AICc | |
| BCLC | 459.6 | 13112.3 | 234.4 | 10568.5 | 250.1 | 4570.8 |
| HKLC | 508.8 | 13063.1 | 289.3 | 10513.6 | 297.4 | 4523.5 |
| CLIP | 594.3 | 12977.7 | 496.2 | 10306.8 | 341.5 | 4479.7 |
| TIS | 483.6 | 13088.4 | 425.0 | 10377.9 | 341.9 | 4479.0 |
| JIS | 372.4 | 13199.6 | 345.2 | 10457.7 | 222.5 | 4598.4 |
| Tokyo | 443.6 | 13128.3 | 387.0 | 10416.0 | 270.5 | 4550.4 |
| TNM | 200.4 | 13371.6 | 178.2 | 10624.7 | 120.8 | 4700.1 |
BCLC, Barcelona Clínic of Liver Cancer; CLIP, Cancer of the Liver Italian Program; HKLC, Hong Kong Liver Cancer; JIS, Japan Integrated Scoring; TNM, tumor-node-metastasis; TIS, Taipei Integrated Scoring.